Logo image of HCWB

HCW BIOLOGICS INC (HCWB) Stock Fundamental Analysis

NASDAQ:HCWB - Nasdaq - US40423R1059 - Common Stock - Currency: USD

0.3387  -0.02 (-5.05%)

Premarket: 0.3403 +0 (+0.47%)

Fundamental Rating

1

HCWB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. HCWB may be in some trouble as it scores bad on both profitability and health. HCWB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

HCWB had negative earnings in the past year.
HCWB had a negative operating cash flow in the past year.
In the past 5 years HCWB always reported negative net income.
In the past 5 years HCWB always reported negative operating cash flow.
HCWB Yearly Net Income VS EBIT VS OCF VS FCFHCWB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

HCWB has a Return On Assets of -140.57%. This is amonst the worse of the industry: HCWB underperforms 81.96% of its industry peers.
Industry RankSector Rank
ROA -140.57%
ROE N/A
ROIC N/A
ROA(3y)-47.84%
ROA(5y)-53.34%
ROE(3y)-83.53%
ROE(5y)-77.23%
ROIC(3y)N/A
ROIC(5y)N/A
HCWB Yearly ROA, ROE, ROICHCWB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

HCWB's Gross Margin of 32.41% is fine compared to the rest of the industry. HCWB outperforms 74.96% of its industry peers.
HCWB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HCWB Yearly Profit, Operating, Gross MarginsHCWB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

HCWB does not have a ROIC to compare to the WACC, probably because it is not profitable.
HCWB has more shares outstanding than it did 1 year ago.
The debt/assets ratio for HCWB is higher compared to a year ago.
HCWB Yearly Shares OutstandingHCWB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
HCWB Yearly Total Debt VS Total AssetsHCWB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -10.45, we must say that HCWB is in the distress zone and has some risk of bankruptcy.
HCWB has a worse Altman-Z score (-10.45) than 73.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.45
ROIC/WACCN/A
WACC8.64%
HCWB Yearly LT Debt VS Equity VS FCFHCWB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.07 indicates that HCWB may have some problems paying its short term obligations.
HCWB has a worse Current ratio (0.07) than 96.85% of its industry peers.
HCWB has a Quick Ratio of 0.07. This is a bad value and indicates that HCWB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.07, HCWB is doing worse than 96.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
HCWB Yearly Current Assets VS Current LiabilitesHCWB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for HCWB have decreased strongly by -66.67% in the last year.
The Revenue has grown by 22.53% in the past year. This is a very strong growth!
HCWB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.50% yearly.
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.95%
Revenue 1Y (TTM)22.53%
Revenue growth 3Y-11.5%
Revenue growth 5YN/A
Sales Q2Q%-50.01%

3.2 Future

HCWB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.65% yearly.
Based on estimates for the next years, HCWB will show a very strong growth in Revenue. The Revenue will grow by 141.38% on average per year.
EPS Next Y16.94%
EPS Next 2Y9.48%
EPS Next 3Y6.65%
EPS Next 5YN/A
Revenue Next Year368.22%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y141.38%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HCWB Yearly Revenue VS EstimatesHCWB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
HCWB Yearly EPS VS EstimatesHCWB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HCWB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HCWB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HCWB Price Earnings VS Forward Price EarningsHCWB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCWB Per share dataHCWB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.48%
EPS Next 3Y6.65%

More info and screens

0

5. Dividend

5.1 Amount

HCWB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HCW BIOLOGICS INC

NASDAQ:HCWB (3/5/2025, 8:00:02 PM)

Premarket: 0.3403 +0 (+0.47%)

0.3387

-0.02 (-5.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-01 2024-04-01/amc
Earnings (Next)N/A N/A
Inst Owners7.02%
Inst Owner Change165.32%
Ins Owners40.57%
Ins Owner Change0%
Market Cap15.09M
Analysts82.86
Price Target3.06 (803.45%)
Short Float %3.4%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)713.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.32
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.08
BVpS-0.22
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -140.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.41%
FCFM N/A
ROA(3y)-47.84%
ROA(5y)-53.34%
ROE(3y)-83.53%
ROE(5y)-77.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 497.59%
Cap/Sales 110.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z -10.45
F-Score3
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)661.14%
Cap/Depr(5y)472.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.95%
EPS Next Y16.94%
EPS Next 2Y9.48%
EPS Next 3Y6.65%
EPS Next 5YN/A
Revenue 1Y (TTM)22.53%
Revenue growth 3Y-11.5%
Revenue growth 5YN/A
Sales Q2Q%-50.01%
Revenue Next Year368.22%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y141.38%
EBIT growth 1Y-73.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-53.18%
OCF growth 3YN/A
OCF growth 5YN/A